Targets › CLU
1 program from 1 company in 1 trial: 1 Phase 2; Oncology.
[Isoform 1]: Functions as extracellular chaperone that prevents aggregation of non native proteins. Prevents stress-induced aggregation of blood plasma proteins. (UniProt, P10909)
Open in Phaseline: the race on CLU, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Alethia Biotherapeutics | Sotevtamab Anti-tumor-associated secreted clusterin (TA-sCLU) monoclonal antibody | CLU | Phase 2 | Metastatic Colorectal Cancer | – |
Metastatic Colorectal Cancer (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.